Magnetic resonance imaging predictors for relapsing Neuromyelitis Optica

• Conditions: Monophasic neuromyelitis Opticarelapses Neuromyelitis Optica; Neuromyelitis optica spectrum; Optic Neuritis; Magnetic Resonance Imaging; anti-aquaporin 4 autoantibody

• Registration Number: TCTR20240314003
• Lead Sponsor: Rajavithi Hospital, Rangsit University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-03-14
• Last Update Posted: 19 August 2024
• Study Completion: 2024-09-30

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

1) Patients diagnosed with NMOSD by a neurologist according to IPND, 2015 diagnostic criteria.
2) The patient has undergone a magnetic resonance imaging (MRI) scan and has the images in the hospital's PAC system.

Exclusion Criteria

1) The follow-up period less than 6 months.
2) Patients with other central nervous system pathologies such as cerebrovascular disease, neurological diseases, and cranial nerve disease.
3) Patients who refuse immunosuppressive treatment prescribed by a neurologists.
4) Incomplete data, or low quality MRI.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
MRI features Within 6 months after stable treatment. Any MRI feature that have predictive value on relapses Neuromyelitis Optica.

Secondary Outcome Measures

Name	Time	Method
Annualized relapse rate (ARR) Within 6 months after stable treatment. Relapses frequency divided by person-time in year.,Relapse NMOSD Within 6 months after stable treatment. Diagnosed by neurologist based on sudden onset of worsening symptom of central nervous system that persisted for morethan 24 hrs, without other explanation causes.